Revenues, Recognition and Allowances (Details Textual) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018 USD ($) transaction_type segment	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) transaction_type	Sep. 30, 2018 USD ($) transaction_type product	Sep. 30, 2018 USD ($) transaction_type	Sep. 30, 2018 USD ($) transaction_type segment	Sep. 30, 2018 USD ($) transaction_type	Sep. 30, 2018 USD ($) transaction_type drug	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Disaggregation of Revenue [Line Items]
Types of transactions | transaction_type	3		3	3	3	3	3	3
Segments | segment	1					1
Accounts receivable		$ 21,226							$ 21,226	$ 12,742
Allowance for doubtful accounts	$ 2,787	2,200	$ 2,787	$ 2,787	$ 2,787	$ 2,787	$ 2,787	$ 2,787	2,200	2,185
Allowance for doubtful accounts related to one customer	1,700		$ 1,700	1,700	1,700	1,700	$ 1,700	1,700
Accounts receivable, terms of customer credit			100 days
Percentage of net sales for royalty							40.00%
Royalties	613	600	$ 613	$ 613	613	613	$ 613	$ 613	600	$ 856
Royalty expense	500	600			2,000				1,400
United States
Disaggregation of Revenue [Line Items]
Products which the company pays royalties				5				5
Products manufactured, marketed and distributed | drug								32
Net Of SRA Balance
Disaggregation of Revenue [Line Items]
Accounts receivable	$ 20,500	$ 31,800	$ 20,500	$ 20,500	$ 20,500	$ 20,500	$ 20,500	$ 20,500	$ 31,800